Table 4.

Prognostic evaluation of clinical and histopatological characteristics of early stages: Overall survival

Overall Survival - Univariated analysis
		HR	Lower 95% CI	Upper 95% CI	p-value
Age at diagnosis		1.04	1.01	1.08	0.019
Stage	I	1
	II	1.37	0.56	3.40	0.492
Grading	G1	1
	G2	3.35	0.74	15.11	0.116
	G3	4.39	1.01	19.10	0.049
Histotype	Serous	1
	Endometroid	0.81	0.28	2.37	0.699
	Clear cell	1.89	0.74	4.80	0.182
	Mucinous	1.06	0.29	3.89	0.930
	Undifferentiated	7.68	1.65	35.81	0.009
	Other	0.67	0.09	5.21	0.699
First line therapy	No therapy	1
	Platinum-based	0.63	0.30	1.33	0.227
KRAS status	Wild-type	1
	Mutated	1.18	0.45	3.11	0.737
KRAS gene copy number	Disomy	1
	Amplification	1.41	0.57	3.49	0.455
	Deletion	0.38	0.05	2.86	0.350
KRAS-LCS6 polymorphism	T/G-G/G	1
	T/T	2.13	0.64	7.05	0.215
Overall Survival - Multivariated analysis
		HR	Lower 95% CI	Upper 95% CI	p-value
KRAS-LCS6 polymorphism	T/G-G/G	1
	T/T	3.11	0.72	13.43	0.129